Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study …
G Margiotta-Casaluci, S Bigliardi, F Cocito… - Frontiers in …, 2023 - frontiersin.org
In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …
A multi-center retrospective analysis of patients with relapsed/refractory follicular lymphoma after third-line chemotherapy
S Fuji, Y Tada, K Nozaki, H Saito, T Ozawa, T Kida… - Annals of …, 2020 - Springer
The overall outcome of patients with advanced-stage follicular lymphoma (FL) has improved
significantly. However, some patients still develop multiple relapsed/refractory FL (RRFL). To …
significantly. However, some patients still develop multiple relapsed/refractory FL (RRFL). To …
[HTML][HTML] Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in …
E Kimby, G Martinelli, B Ostenstad, UJM Mey, D Rauch… - Blood, 2014 - Elsevier
Background: Previous trials from the Swiss Group for Clinical Cancer Research (SAKK) and
the Nordic Lymphoma Group (NLG) showed that therapy with single-agent rituximab can …
the Nordic Lymphoma Group (NLG) showed that therapy with single-agent rituximab can …
Rituximab plus CVP chemotherapy vs. CVP alone as first-line treatment for follicular lymphoma: Treatment effect according to baseline prognostic factors
K Imrie, A Belch, R Pettengell, A Rueda… - Journal of Clinical …, 2005 - ascopubs.org
6525 Background: In patients with advanced previously untreated follicular lymphoma (FL),
the addition of 8 cycles of rituximab to standard CVP (cyclophosphamide, vincristine …
the addition of 8 cycles of rituximab to standard CVP (cyclophosphamide, vincristine …
Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.
8049 Background: The National LymphoCare Study (NLCS) collects data on disease
presentation, treatment patterns, and clinical outcomes for 2736 patients with with follicular …
presentation, treatment patterns, and clinical outcomes for 2736 patients with with follicular …
Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma
J Yared, A Kimball, MR Baer, H Bahrain… - … Lymphoma Myeloma and …, 2013 - Elsevier
Abstract Introduction The PRIMA (Primary Rituximab and Maintenance) study established 2
years of maintenance rituximab (MR) as a standard of care for follicular lymphoma (FL) …
years of maintenance rituximab (MR) as a standard of care for follicular lymphoma (FL) …
[HTML][HTML] Rituximab maintenance improves overall survival of patients with follicular lymphoma—individual patient data meta-analysis
L Vidal, A Gafter-Gvili, G Salles, S Bousseta… - European Journal of …, 2017 - Elsevier
Background Randomised trials of rituximab maintenance (MR) for patients with follicular
lymphoma support improved progression-free survival (PFS), but the effect on overall …
lymphoma support improved progression-free survival (PFS), but the effect on overall …
Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular …
W Hiddemann, E Hoster, C Buske, M Dreyling… - 2006 - ashpublications.org
Recent reports have shown a significant improvement of overall survival (OS) in patients
with advanced stage follicular lymphoma (FL) over the last few decades. In order to identify …
with advanced stage follicular lymphoma (FL) over the last few decades. In order to identify …
[HTML][HTML] Life expectancy in follicular lymphoma is mainly determined by response to first LINE treatment: a long-term survey on 597 patients
C Tarella, A Gueli, F Delaini, AM Barbui, R Bruna… - Blood, 2015 - Elsevier
BACKGROUND Follicular lymphoma (FL) is the most common indolent form of non-
Hodgkin's lymphoma. However, FL is a heterogeneous disorder and in a proportion of …
Hodgkin's lymphoma. However, FL is a heterogeneous disorder and in a proportion of …
[HTML][HTML] Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) …
Background: Bendamustine and rituximab (BR) has been a preferred regimen for frontline
therapy of patients (pts) with advanced stage follicular lymphoma (FL) since randomized …
therapy of patients (pts) with advanced stage follicular lymphoma (FL) since randomized …